Information Provided By: 
Fly News Breaks for August 13, 2018
IDRA, BCRX
Aug 13, 2018 | 07:14 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for BioCryst Pharmaceuticals (BCRX) to $13 and reiterates a Buy rating on the shares. The analyst says that based on the proxy statement of the failed merger with Idera Pharmaceuticals (IDRA) and his diligence on the treatment landscape, hereditary angioedema will continue to be a field of consolidation interest. He believes this "should add meaningful albeit less quantifiable premium" to BioCryst's valuation.
News For BCRX;IDRA From the Last 2 Days
There are no results for your query BCRX;IDRA
